Targeted Systemic Therapy of Prostate Cancer With a Monoclonal Antibody to Prostate-Specific Membrane Antigen

Seminars in Oncology

Volumn 30, Issue 5, 2003, Pages 667-676

  Bander, Neil H ^a   Nanus, David M ^a   Milowsky, Matthew I ^a   Kostakoglu, Lale ^a   Vallabahajosula, Shankar ^a   Goldsmith, Stanley J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CAPROMAB PENDETIDE IN 111; CYTOTOXIN; IMMUNOGLOBULIN G ANTIBODY; INDIUM 111; J 591; LUTETIUM; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; YTTRIUM 90;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; CELL MEMBRANE; CLINICAL TRIAL; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOELECTRON MICROSCOPY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR;

EID: 0142030952     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00358-0     Document Type: Article

References (32)

1. Allen TM: Ligand, targeted therapeutics in anticancer therapy. Nat Rev Cancer 2:750-763, 2002
2. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7:927-936, 1987
3. Israeli RS, Powell CT, Fair WR, et al: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53:227-230, 1994
4. Israeli RS, Powell CT, Fair WR, et al: Expression of the prostate-specific membrane antigen. Cancer Res 54:1807-1811, 1994
5. Wright GL Jr, Haley C, Beckett ML, et al: Expression of prostate-specific membrane antigen (PSMA) in normal, benign and malignant prostate tissues. Urol Oncol 1:18-28, 1995
6. Troyer JK, Beckett ML, Wright GL Jr: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62: 552-558, 1995
7. Sokoloff RL, Norton KC, Gasior CL, et al: A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. Prostate 43: 150-157, 2000
8. Bostwick DG, Pacelli A, Blute M, et al: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 82:2256-2261, 1998
9. Wright GLJ, Grob BM, Haley C, et al: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326-334, 1996
10. Sweat SD, Pacelli A, Murphy GP, et al: PSMA expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52:637-640, 1998
11. Pinto JT, Suffoletto B, Berzin TM, et al: Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2:1445-1451, 1996
12. Kahn D, Williams RD, Manyak MJ: The ProstaScint Study Group: 111 Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol 159:2041-2046, 1998
13. Kahn D, Williams RD, Haseman MK, et al: Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 16:284-289, 1998
14. Troyer JK, Beckett ML, Wright GL Jr: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62: 552-558, 1995
15. Yao D, Trabulsi EJ, Kostakoglu L, et al: The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol 20:211-218, 2002
16. Troyer JK, Feng Q, Beckett ML, et al: Biochemical characterization and mapping of the 7El 1-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol 1:29-37, 1995
17. Troyer JK, Beckett ML, Wright GL Jr: Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30:232-242, 1997
18. Liu H, Moy P, Kim S, et al: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57: 3629-3634, 1997
19. Liu H, Rajasekaran AK, Moy P, et al: Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58:4055-4060, 1998
20. McDevitt MR, Barendswaard E, Ma D, et al: An alphaparticle emitting antibody for radioimmunotherapy of prostate cancer. Cancer Res 60:6095-6100, 2000
21. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 60:5237-5243, 2000
22. Rawlings ND, Barrett AJ: Structure of membrane glutamate carboxypeptidase. Biochim Biophys Acta 1339:247-252, 1997
23. Smith-Jones PM, Vallabhajosula S, Navarro V, et al: Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 44:610-617, 2003
24. Adams GP, Schier R, McCall AM, et al: High affinity restricts the localization of tumor penetration of single-chain fv antibody molecules. Cancer Res 62:4750-4755
25. Hamilton A, King S, Liu H, et al: A novel humanised antibody against prostate specific membrane antigen (PSMA) for in vivo targeting and therapy. Proc Am Assoc Cancer Res 39:440, 1998 (abstr)
26. Issell BF, Crooke ST: Maytansine. Cancer Treat Rev 5:199-207, 1978
27. Bander NH, Nanus D, Bremer S, et al: Clinical trial targeting a monoclonal antibody to the extracellular domain of prostate specific membrane antigen (PSMAext) in patients with hormone-independent prostate cancer. Proc Am Soc Clin Oncol 19:477A, 2000 (abstr)
28. Bander NH, Nanus D, Goldsmith SJ, et al: Phase I trial of humanized monoclonal antibody to prostate specific membrane antigen/extracellular domain. Proc Am Soc Clin Oncol 20:181a, 2001 (abstr)
29. Bander NH, Trabulsi EJ, Kostakoglu L, et al: Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol (in press)
30. Chang SS, Reuter VE, Heston WDW, et al: Five different anti-PSMA antibodies confirm prostate-specific membrane antigen (PSMA) expression in tumor-associated neovasculature. Cancer Res 59:3192-3198, 1999
31. Gong MC, Chang SS, Sadelain M, et al: Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metast Rev 18:483-490, 1999
32. Milowsky MI, Rosmarin AS, Cobham MV, et al: Anti-PSMA mAb HuJ591 specifically targets tumor vascular endothelial cells in patients with advanced solid tumor malignancies. Proc Am Soc Clin Oncol 21:29, 2002 (abstr)